Spondylodiscitis after transoral robotic surgery: Retrospective 7-case series from the GETTEC group.


Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 25 3 2019
medline: 27 12 2019
entrez: 26 3 2019
Statut: ppublish

Résumé

Cervical spondylodiscitis is a rare but severe complication of pharyngeal surgery. This multicenter retrospective study reported all patients in the database of the French head and neck tumor study group (GETTEC) affected by cervical spondylodiscitis after transoral robotic surgery (TORS) for malignant pharyngeal tumor from January 2010 to January 2017. To describe cases of post-TORS cervical spondylodiscitis, identify alarm signs, and determine optimal management of these potentially lethal complications. Seven patients from 6 centers were included. Carcinomas were located in the posterior pharyngeal wall. Tumor stage was T1 or T2. All patients had risk factors for spondylodiscitis. Mean time to diagnosis was 12.6days. The interval between surgery and spondylodiscitis diagnosis ranged from 20days to 4.5months, for a mean 2.1months. The most common symptom was neck pain (87%). Infections were polymicrobial; micro-organisms were isolated in 5 cases and managed by intravenous antibiotics, associated to medullary decompression surgery in 3 cases. Follow-up found favorable progression in 4 cases, and 3 deaths (mortality, 43%). This French multicenter study found elevated mortality in post-TORS spondylodiscitis, even in case of limited resection. Surgeons must be aware of this complication and alerted by persistent neck pain, fever, asthenia, impaired or delayed posterior pharyngeal wall wound healing or elevation of inflammatory markers. MRI is the most effective diagnostic radiological examination.

Sections du résumé

BACKGROUND BACKGROUND
Cervical spondylodiscitis is a rare but severe complication of pharyngeal surgery.
MATERIAL AND METHODS METHODS
This multicenter retrospective study reported all patients in the database of the French head and neck tumor study group (GETTEC) affected by cervical spondylodiscitis after transoral robotic surgery (TORS) for malignant pharyngeal tumor from January 2010 to January 2017.
OBJECTIVES OBJECTIVE
To describe cases of post-TORS cervical spondylodiscitis, identify alarm signs, and determine optimal management of these potentially lethal complications.
RESULTS RESULTS
Seven patients from 6 centers were included. Carcinomas were located in the posterior pharyngeal wall. Tumor stage was T1 or T2. All patients had risk factors for spondylodiscitis. Mean time to diagnosis was 12.6days. The interval between surgery and spondylodiscitis diagnosis ranged from 20days to 4.5months, for a mean 2.1months. The most common symptom was neck pain (87%). Infections were polymicrobial; micro-organisms were isolated in 5 cases and managed by intravenous antibiotics, associated to medullary decompression surgery in 3 cases. Follow-up found favorable progression in 4 cases, and 3 deaths (mortality, 43%).
CONCLUSION CONCLUSIONS
This French multicenter study found elevated mortality in post-TORS spondylodiscitis, even in case of limited resection. Surgeons must be aware of this complication and alerted by persistent neck pain, fever, asthenia, impaired or delayed posterior pharyngeal wall wound healing or elevation of inflammatory markers. MRI is the most effective diagnostic radiological examination.

Identifiants

pubmed: 30905532
pii: S1879-7296(19)30047-X
doi: 10.1016/j.anorl.2019.03.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

179-183

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

C Carpentier (C)

Service d'ORL et chirurgie cervico-faciale, CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France.

C Bobillier (C)

Service d'ORL et chirurgie cervico-faciale, CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France.

D Blanchard (D)

Service d'ORL et chirurgie cervico-faciale, centre François-Baclesse, 3, avenue du Général-Harris, 14000 Caen, France.

B Lallemant (B)

Service d'ORL et chirurgie cervico-faciale, CHU Carémeau, place du Pr.-Robert-Debré, 30029 Nîmes cedex 9, France.

R Garrel (R)

Service d'ORL et chirurgie cervico-faciale, CHU Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34090 Montpellier, France.

P Gorphe (P)

Service d'ORL et chirurgie cervico-faciale, Institut Gustave-Roussy, 114, rue Édouard-Vaillant, 94800 Villejuif, France.

R Mastronicola (R)

Service d'ORL et chirurgie cervico-faciale, Institut de Cancérologie de Lorraine Alexis-Vautrin, 6, avenue de Bourgogne, 54500 Vandœuvre-lès-Nancy, France.

S Morinière (S)

Service d'ORL et chirurgie cervico-faciale, CHU Bretonneau, 2, boulevard Tonnellé, 37000 Tours, France. Electronic address: sylvain.moriniere@univ-tours.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH